Severe Asthma Market Forecast by 2032: Epidemiology Analysis, Emerging Therapies, Regulatory Updates by DelveInsight | Sanofi, GlaxoSmithKline, EMS, Oneness Biotech, Incyte Crp, CSPC ZhongQi Pharma

Posted on
by

Severe Asthma Market Forecast by 2032: Epidemiology Analysis, Emerging Therapies, Regulatory Updates by DelveInsight | Sanofi, GlaxoSmithKline, EMS, Oneness Biotech, Incyte Crp, CSPC ZhongQi Pharma
The Severe Asthma Market size was valued approximately USD 7 billion in 2022 and the report offers an in-depth understanding of the Severe Asthma, historical and forecasted epidemiology as well as the Severe Asthma market trends in the 7MM.

DelveInsight’s “Severe Asthma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Severe Asthma, historical and forecasted epidemiology as well as the Severe Asthma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Severe Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Asthma Market Forecast

 

Some of the key facts of the Severe Asthma Market Report: 

  • The Severe Asthma market size was valued approximately USD 7 billion in 2022 and is anticipated to grow with a significant CAGR of 5% during the study period (2019-2032)

  • In March 2024, Upstream Bio has initiated patient dosing in its Phase II VALIANT clinical trial of verekitug (UPB-101) for severe asthma. This trial focuses on assessing the effectiveness of verekitug, a recombinant fully human immunoglobulin G1 monoclonal antibody, which works by blocking the thymic stromal lymphopoietin receptor (TLSPR) to counteract TSLP-driven inflammation. The VALIANT trial, conducted in a randomized, double-blind, placebo-controlled manner, spans a 24-week dosing regimen with the goal of determining verekitug’s potential as a top-tier treatment option for severe asthma.

  • In January 2024, GSK has been granted approval by the China National Medical Products Administration for Nucala (mepolizumab) as an additional maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older. Nucala, the first-in-class monoclonal antibody that targets anti-interleukin-5 (IL-5), was initially approved in the US in 2015 for severe asthma with an eosinophilic phenotype. Mepolizumab functions by attaching to and blocking IL-5 molecules.

  • In August 2023, Tezspire (tezepelumab-ekko) is a pioneering human monoclonal antibody designed for additional maintenance therapy for severe asthma in adults and adolescents aged 12 years and older who are unresponsive to their current asthma medications. It stands out as the inaugural biologic choice for severe asthma, regardless of any specific phenotypic or biomarker constraints within its approved usage parameters. 

  • In the European region, the United Kingdom boasted the largest market size, amounting to USD 399 million in 2022, whereas Spain reported the smallest market size during the same period.

  • DelveInsight’s projections suggest that in 2022, the total diagnosed prevalent cases of asthma across the 7MM were approximately 54,898,928. Among these cases, adults represented the majority of diagnosed prevalent cases. It is anticipated that these numbers will continue to rise by the year 2032.

  • In the United States, the adult population accounted for approximately 20,643,622 diagnosed prevalent cases of asthma, while the pediatric population had around 5,191,158 cases, totaling approximately 25,834,780 diagnosed prevalent cases of asthma. These figures are projected to experience substantial growth at a significant compound annual growth rate (CAGR) from 2023 to 2032.

  • In 2022, the United Kingdom had the highest count of diagnosed prevalent asthma cases, including both adults and pediatric cases, totaling 8,396,431. Following closely, Germany recorded 4,937,062 cases among the EU4 and the UK countries.

  • In 2022, the UK reported the highest number of diagnosed prevalent asthma cases, comprising both adults and pediatric cases, reaching a total of 8,396,431. In comparison, Germany closely followed with 4,937,062 cases among the EU4 and UK nations.

  • The Severe Asthma pipeline is dynamic and includes promising candidates such as GSK3511294 (Depemokimab) by GlaxoSmithKline, PT010 (Breztri/Trixeo/BGF MDI) by AstraZeneca, among others, anticipated to be launched between 2023 and 2032.

  • Key Severe Asthma Companies: Upstream Bio Inc., Oneness Biotech Co., Chia Tai Tianqing Pharmaceutical, Nantes University Hospital, Hamad Medical Corporation, Incyte Corporation, CSPC ZhongQi Pharmaceutical, AstraZeneca, Sunshine Guojian Pharmaceutical, Amgen, Areteia Therapeutics, Sanofi, GlaxoSmithKline, EMS, Advagene Biopharma Co., Teva Branded Pharmaceutical, and others

  • Key Severe Asthma Therapies: Verekitug (UPB-101), FB704A, TQC2731 injection, Benralizumab Prefilled Syringe, Nebulized budesonide, povorcitinib, CM326, CM310, Benralizumab, 610, Rocatinlimab, Dexpramipexole Dihydrochloride, Amlitelimab, GSK3511294 (Depemokimab), Mepolizumab, Flamboyant 200/12, AD17002, TEV-56248, FB825, and others

  • The Severe Asthma epidemiology based on gender analyzed that females are more susceptible to suffering from asthma when compared to the male population, in the 7MM

  • The Severe Asthma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Asthma pipeline products will significantly revolutionize the Severe Asthma market dynamics.

 

Severe Asthma Overview

Severe asthma, also known as refractory or difficult-to-treat asthma, is a subtype of asthma characterized by persistent and poorly controlled symptoms despite treatment with high-dose inhaled corticosteroids and other asthma medications. Individuals with severe asthma often experience frequent exacerbations, reduced lung function, and a significant impact on their quality of life.

 

Get a Free sample for the Severe Asthma Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/severe-asthma-market

 

Severe Asthma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Severe Asthma Epidemiology Segmentation:

The Severe Asthma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Severe Asthma

  • Prevalent Cases of Severe Asthma by severity

  • Gender-specific Prevalence of Severe Asthma

  • Diagnosed Cases of Episodic and Chronic Severe Asthma

 

Download the report to understand which factors are driving Severe Asthma epidemiology trends @ Severe Asthma Epidemiology Forecast

 

Severe Asthma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Asthma market or expected to get launched during the study period. The analysis covers Severe Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Severe Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Severe Asthma Therapies and Key Companies

  • Verekitug (UPB-101): Upstream Bio Inc.

  • FB704A: Oneness Biotech Co.

  • TQC2731 injection: Chia Tai Tianqing Pharmaceutical

  • Benralizumab Prefilled Syringe: Nantes University Hospital

  • Nebulized budesonide: Hamad Medical Corporation

  • povorcitinib: Incyte Corporation

  • CM326: CSPC ZhongQi Pharmaceutical

  • CM310: CSPC ZhongQi Pharmaceutical

  • Benralizumab: AstraZeneca

  • 610: Sunshine Guojian Pharmaceutical

  • Rocatinlimab: Amgen

  • Dexpramipexole Dihydrochloride: Areteia Therapeutics

  • Amlitelimab: Sanofi

  • GSK3511294 (Depemokimab): GlaxoSmithKline

  • Mepolizumab: GlaxoSmithKline

  • Flamboyant 200/12: EMS

  • AD17002: Advagene Biopharma Co.

  • TEV-56248: Teva Branded Pharmaceutical

  • FB825: Oneness Biotech Co.

 

Discover more about therapies set to grab major Severe Asthma market share @ Severe Asthma Treatment Landscape

 

Severe Asthma Market Strengths

  • Robust pipeline for severe asthma with potential medicines targeting a variety of different and more effective pathogenic mechanisms in asthma.

 

Severe Asthma Market Opportunities

  • To evaluate new candidate pharmacological interventions for severe asthma management in pediatric patient pool for which not many therapies are approved.

 

Scope of the Severe Asthma Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Severe Asthma Companies: Upstream Bio Inc., Oneness Biotech Co., Chia Tai Tianqing Pharmaceutical, Nantes University Hospital, Hamad Medical Corporation, Incyte Corporation, CSPC ZhongQi Pharmaceutical, AstraZeneca, Sunshine Guojian Pharmaceutical, Amgen, Areteia Therapeutics, Sanofi, GlaxoSmithKline, EMS, Advagene Biopharma Co., Teva Branded Pharmaceutical, and others

  • Key Severe Asthma Therapies: Verekitug (UPB-101), FB704A, TQC2731 injection, Benralizumab Prefilled Syringe, Nebulized budesonide, povorcitinib, CM326, CM310, Benralizumab, 610, Rocatinlimab, Dexpramipexole Dihydrochloride, Amlitelimab, GSK3511294 (Depemokimab), Mepolizumab, Flamboyant 200/12, AD17002, TEV-56248, FB825, and others

  • Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies

  • Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Severe Asthma Unmet Needs, KOL’s views, Analyst’s views, Severe Asthma Market Access and Reimbursement 

 

To know more about Severe Asthma companies working in the treatment market, visit @ Severe Asthma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Severe Asthma Market Report Introduction

2. Executive Summary for Severe Asthma

3. SWOT analysis of Severe Asthma

4. Severe Asthma Patient Share (%) Overview at a Glance

5. Severe Asthma Market Overview at a Glance

6. Severe Asthma Disease Background and Overview

7. Severe Asthma Epidemiology and Patient Population

8. Country-Specific Patient Population of Severe Asthma 

9. Severe Asthma Current Treatment and Medical Practices

10. Severe Asthma Unmet Needs

11. Severe Asthma Emerging Therapies

12. Severe Asthma Market Outlook

13. Country-Wise Severe Asthma Market Analysis (2019–2032)

14. Severe Asthma Market Access and Reimbursement of Therapies

15. Severe Asthma Market Drivers

16. Severe Asthma Market Barriers

17.  Severe Asthma Appendix

18. Severe Asthma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/